4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER

被引：226

作者：

COOMBES, RC

GOSS, P

DOWSETT, M

GAZET, JC

BRODIE, A

机构：

[1] ROYAL MARSDEN HOSP, CANC RES CAMPAIGN LABS, SUTTON SM2 5PX, SURREY, ENGLAND

[2] UNIV MARYLAND, SCH MED, DEPT PHARMACOL & EXPTL THERAPEUT, BALTIMORE, MD 21201 USA

[3] CHELSEA HOSP WOMEN, DEPT ENDOCRINOL, LONDON SW3, ENGLAND

来源：

LANCET | 1984年 / 2卷 / 8414期

关键词：

D O I：

10.1016/S0140-6736(84)92795-8

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4-Hydroxyandrostenedione, a potent inhibtor of the aromatase (estrogen synthetase) system, was given to 11 patients with metastatic breast cancer. After a single 500 mg i.m. injection a sustained reduction of serum estradiol was observed for at least 1 wk in all patients in whom the steroid was measured. Patients (4) responded to treatment for periods of up to 4 mo. and healing of bone metastases and reduction in size of soft-tissue metastases was evident. The only side-effects were pain at the injection site and hot flushes. 4-Hydroxyandrostenedione is a new and specific aromatase inhibitor which shows promise in the treatment of paitemts with metastatic breast cancer.

引用

页码：1237 / 1239

页数：3

共 12 条

[1] INACTIVATION OF AROMATASE INVITRO BY 4-HYDROXY-4-ANDROSTENE-3, 17-DIONE AND 4-ACETOXY-4-ANDROSTENE-3, 17-DIONE AND SUSTAINED EFFECTS INVIVO [J].